Investors

Introduction

At Alcobra, we remain deeply committed to developing safe and effective products for the treatment of cognitive disorders including ADHD and Fragile X Syndrome and continuing to deliver value for our stockholders.

Our Investor Relations section is designed to provide you with easy access to company information.

NASDAQ: ADHD

$ 1.12

4:00 PM | May 25, 2017
$0.00
(0.00%)

Day High: N/A
Day Low:  N/A
Volume:    N/A
Delayed ~20 min., by eSignal.


Events & Presentations

Mar 28, 2017 / 8:00 AM ET